West Pharmaceutical Services CapEx decreased by 43.9% to $42.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 40.1%, from $71.30M to $42.70M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 3.1% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $56.90M | $65.30M | $76.50M | $65.80M | $66.10M | $57.80M | $94.90M | $82.10M | $75.40M | $95.80M | $108.70M | $90.60M | $100.20M | $81.30M | $104.90M | $71.30M | $75.20M | $63.30M | $76.10M | $42.70M |
| QoQ Change | — | +14.8% | +17.2% | -14.0% | +0.5% | -12.6% | +64.2% | -13.5% | -8.2% | +27.1% | +13.5% | -16.7% | +10.6% | -18.9% | +29.0% | -32.0% | +5.5% | -15.8% | +20.2% | -43.9% |
| YoY Change | — | — | — | — | +16.2% | -11.5% | +24.1% | +24.8% | +14.1% | +65.7% | +14.5% | +10.4% | +32.9% | -15.1% | -3.5% | -21.3% | -25.0% | -22.1% | -27.5% | -40.1% |